The use of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide concentrations to guide diagnosis and treatment of patent ductus arteriosus in preterm infants
10.3760/cma.j.issn.1008-1372.2016.08.046
- VernacularTitle:B型利钠肽和氮端B型利钠肽原在早产儿动脉导管未闭诊治的研究进展
- Author:
Ying LIU
;
Yuxin ZHOU
- Publication Type:Journal Article
- Keywords:
Natriuretic peptide,brain/ME;
Ductus arteriosus,patent/DI/TH;
Infant,premature;
Review
- From:
Journal of Chinese Physician
2016;18(8):1272-1275
- CountryChina
- Language:Chinese
-
Abstract:
The high morbidity and compliments of patent ductus arteriosus (PDA) in preterm infants are reported,but the diagnostic and prognostic appraisal of PDA is still debatable.The B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are found efficient in diagnosis of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm infants,and also helpful in therapy decisions and prediction of treatment response.However,the type of assay and cut-off values have not yet reached a consent,so that further researches are needed.
